New supplement trial targets gut bacteria overgrowth
NCT ID NCT07215676
First seen Nov 01, 2025 · Last updated Apr 26, 2026 · Updated 23 times
Summary
This early-stage trial will test a nutritional supplement (AV1PD1A) in 10 adults with hydrogen-dominant small intestinal bacterial overgrowth (SIBO). The main goal is to check if the supplement is safe and well-tolerated over 8 weeks. Participants will take three capsules daily and attend clinic visits for blood tests and symptom questionnaires. This is a small, open-label pilot study with no comparison group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL INTESTINAL BACTERIAL OVERGROWTH SYNDROME (SIBO) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NUNM - Helfgott Research Institute
Portland, Oregon, 97201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.